|Chemical and physical data|
|Molar mass||447.64 g/mol g·mol−1|
|3D model (JSmol)|
NESS-040C5 is a potent cannabinoid agonist which was developed for the treatment of glaucoma. It has reasonable selectivity for the CB2 receptor subtype, having a CB2 affinity of 0.4nM, and 25x selectivity over the related CB1 receptor.
- Paolo Lazzari et al. Pharmaceutical Compounds. US Patent 8106218
- Hanus LO, Mechoulam R. "Novel natural and synthetic ligands of the endocannabinoid system". Current Medicinal Chemistry. 17 (14): 1341–59. doi:10.2174/092986710790980096. PMID 20166928.